Santini recently retired from a 27-year career at Eli Lilly, where he was most recently senior vice president of corporate strategy and business development.
A spokesperson for Allena said of his new role: “The Allena founding team has successfully worked with Mr. Santini in the past and his strategic insights and proven expertise will be of significant value to the company as it accelerates the development of its non-systemic protein therapeutics.”
Our weekly round-up of the bright young things and big cheeses in pharmaceuticals.
The latest changes at Bayer, biopharma, and the winner of Professional Woman of the Year in this...
This week's pharmaceutical changes begin with the election of Reuters' head to the Board of Pfizer.